Medistim ASA (FRA:MD1)

Q3 2025 Medistim ASA Earnings Call Transcript

Oct 24, 2025 / 07:00 AM GMT

Release Date Price: €21.9 (+2.34%)

Transcript

Key Points

Positve

Medistim ASA (FRA:MD1) reported its best third quarter ever for both sales and revenues, with a 25.7% growth in revenues.
The company achieved a significant 27.1% growth in EBIT, reaching 40.6 million NOK.
The Americas region showed strong performance, contributing 63% of the total nominal growth, with a 35.7% increase in sales.
Asia Pacific region delivered an impressive 194% growth, driven by strong sales in China and Japan.
The company's imaging products saw a 73% increase in unit sales, indicating strong market demand and interest.

Negative

The EMEA region experienced a decline in sales, particularly in the European markets like Spain, Germany, and Scandinavia.
Operating expenses increased significantly due to higher commissions, bonuses, and travel expenses, impacting overall profitability.
The vascular product segment showed slower growth this quarter, only increasing by 3.7%.
Despite strong sales, the cost of goods sold and gross margin increased by 1.2%, indicating pressure on profit margins.
The company faces challenges in fully penetrating the EMEA market, with growth relying on conversion to imaging products and new market development.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MEDI.OL - Medistim ASA
Q3 2025 Medistim ASA Earnings Call
Oct 24, 2025 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone and welcome to the presentation of Medicine's 3rd quarter results.

So my name is Cardi Grokster, and I have my CFO Thomas Jacobsen with me, and we will take you through the results.

Before entering into the highlights, I would like to remind ourselves on our track record and our commitment to deliver profitable growth consistently over time and as these graphs are describing, that is a promise we have delivered on.

So let's look into the highlights for the 3rd quarter.

And after a record start of the year, with the first half, providing records both for sales and revenues, I'm very happy to present our best 3rd quarter ever for both sales and revenues or operating profits.

We can

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.